Kentaro Tanaka

TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR-mutated lung cancer

Y. Yoneshima, E. Iwama, R. Ibusuki, 2024, NPJ precision oncology.

Osimertinib readministration for central nervous system metastases in non-small cell lung cancer positive for EGFR activating mutations.

Y. Yoneshima, E. Iwama, Y. Shiraishi, 2024, Respiratory investigation.